Table 3.
Univariate and multivariate analysis of overall survival in patients with NSCLC
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Variables | HR (95 % CI) | p value | HR (95 % CI) | p value |
| Age (>60 vs. ≤ 60) | 0.948 (0.494–1.818) | 0.872 | ||
| Gender (male vs. female) | 2.344 (0.978–5.616) | 0.056 | ||
| Smoking index (≥400 vs. <400) | 1.350 (0.711–2.564) | 0.359 | ||
| Pathological category (Sq. vs. Ad.) | 0.887 (0.429–1.834) | 0.746 | ||
| Pathologic grade (1, 2 vs. 3) | 1.296 (0.833–2.018) | 0.251 | ||
| Tumor stage (II, III, IV vs. I) | 2.093(1.035–4.231) | 0.040a | 1.212(0.417–3.518) | 0.724 |
| Lymph node metastasis (Yes vs. No) | 2.159 (1.115–4.180) | 0.022a | 2.147 (1.109–4.154) | 0.023a |
| Treatment (CIT vs. control) | 0.476(0.244–0.932) | 0.030a | 0.479 (0.245–0.937) | 0.031a |
a
p < 0.05.
Abbreviations: NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval; Sq., Squamous carcinoma; Ad., Adenocarcinoma; CIT, cellular immunotherapy.